Does hepatitis B surface antigen kinetics, including both decline and reaching a threshold, improve prediction of response?

Authors


  • Potential conflict of interest: Dr. Patel is a consultant for Novartis and received grants from GlaxoSmithKline. He also advises and is on the speakers' bureau of Gilead.

No abstract is available for this article.

Ancillary